Correlation Between Bank of America and BioCryst Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Bank of America and BioCryst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bank of America and BioCryst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bank of America and BioCryst Pharmaceuticals, you can compare the effects of market volatilities on Bank of America and BioCryst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bank of America with a short position of BioCryst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bank of America and BioCryst Pharmaceuticals.
Diversification Opportunities for Bank of America and BioCryst Pharmaceuticals
-0.26 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Bank and BioCryst is -0.26. Overlapping area represents the amount of risk that can be diversified away by holding Bank of America and BioCryst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioCryst Pharmaceuticals and Bank of America is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bank of America are associated (or correlated) with BioCryst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioCryst Pharmaceuticals has no effect on the direction of Bank of America i.e., Bank of America and BioCryst Pharmaceuticals go up and down completely randomly.
Pair Corralation between Bank of America and BioCryst Pharmaceuticals
Considering the 90-day investment horizon Bank of America is expected to generate 0.41 times more return on investment than BioCryst Pharmaceuticals. However, Bank of America is 2.43 times less risky than BioCryst Pharmaceuticals. It trades about 0.05 of its potential returns per unit of risk. BioCryst Pharmaceuticals is currently generating about 0.0 per unit of risk. If you would invest 3,278 in Bank of America on August 26, 2024 and sell it today you would earn a total of 1,422 from holding Bank of America or generate 43.38% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Bank of America vs. BioCryst Pharmaceuticals
Performance |
| Timeline |
| Bank of America |
| BioCryst Pharmaceuticals |
Bank of America and BioCryst Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Bank of America and BioCryst Pharmaceuticals
The main advantage of trading using opposite Bank of America and BioCryst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bank of America position performs unexpectedly, BioCryst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will offset losses from the drop in BioCryst Pharmaceuticals' long position.| Bank of America vs. Toronto Dominion Bank | Bank of America vs. Nu Holdings | Bank of America vs. HSBC Holdings PLC | Bank of America vs. Bank of Montreal |
| BioCryst Pharmaceuticals vs. TG Therapeutics | BioCryst Pharmaceuticals vs. Axsome Therapeutics | BioCryst Pharmaceuticals vs. Seres Therapeutics | BioCryst Pharmaceuticals vs. Madrigal Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |